Bioequivalence Study of Famitinib Malate in Healthy Volunteers Under Fasting Condition

NCT05336279 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor

Interventions

DRUG: famitinib malate T(5 mg*4)、famitinib malate R(20 mg)
DRUG: famitinib malate T(5 mg*4)、famitinib malate R(20 mg)

Sponsor

Jiangsu HengRui Medicine Co., Ltd.